MiNK Therapeutics (INKT) Competitors $0.52 +0.02 (+4.76%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INKT vs. RANI, ASRT, ANIX, ADAG, PWUP, CTMX, ME, ANL, KPTI, and RVPHShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Rani Therapeutics (RANI), Assertio (ASRT), Anixa Biosciences (ANIX), Adagene (ADAG), PowerUp Acquisition (PWUP), CytomX Therapeutics (CTMX), 23andMe (ME), Adlai Nortye (ANL), Karyopharm Therapeutics (KPTI), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Rani Therapeutics Assertio Anixa Biosciences Adagene PowerUp Acquisition CytomX Therapeutics 23andMe Adlai Nortye Karyopharm Therapeutics Reviva Pharmaceuticals MiNK Therapeutics (NASDAQ:INKT) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership. Do insiders & institutionals believe in INKT or RANI? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 19.7% of MiNK Therapeutics shares are held by insiders. Comparatively, 53.3% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer INKT or RANI? Rani Therapeutics received 16 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. Likewise, 81.58% of users gave Rani Therapeutics an outperform vote while only 75.00% of users gave MiNK Therapeutics an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% Rani TherapeuticsOutperform Votes3181.58% Underperform Votes718.42% Which has more volatility and risk, INKT or RANI? MiNK Therapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Does the media prefer INKT or RANI? In the previous week, Rani Therapeutics had 3 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for Rani Therapeutics and 1 mentions for MiNK Therapeutics. Rani Therapeutics' average media sentiment score of 1.43 beat MiNK Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate INKT or RANI? MiNK Therapeutics presently has a consensus target price of $6.50, suggesting a potential upside of 1,140.46%. Rani Therapeutics has a consensus target price of $11.71, suggesting a potential upside of 736.73%. Given MiNK Therapeutics' higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Rani Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is INKT or RANI more profitable? MiNK Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% Rani Therapeutics N/A -219.64%-56.71% Which has preferable valuation and earnings, INKT or RANI? MiNK Therapeutics has higher earnings, but lower revenue than Rani Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$0.39-1.34Rani Therapeutics$2.72M29.49-$33.97M-$1.06-1.32 SummaryRani Therapeutics beats MiNK Therapeutics on 12 of the 17 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.72M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-1.3446.7391.4117.18Price / SalesN/A411.851,113.72116.79Price / CashN/A182.1042.7137.86Price / Book-1.013.894.794.78Net Income-$22.46M-$42.21M$120.07M$225.60M7 Day Performance-14.94%-2.15%-1.92%-1.23%1 Month Performance-24.07%4.20%11.46%3.36%1 Year Performance-48.37%18.39%30.49%16.59% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.2401 of 5 stars$0.52+4.8%$6.50+1,140.5%-47.6%$20.72MN/A-1.3430Gap UpRANIRani Therapeutics3.4495 of 5 stars$1.61-3.0%$11.71+627.6%-55.1%$92.24M$2.72M-1.57110Positive NewsASRTAssertio3.3731 of 5 stars$0.95+3.3%$3.25+242.1%-14.8%$90.70M$125.76M-1.2620Gap DownANIXAnixa Biosciences2.9585 of 5 stars$2.80-1.8%$8.50+203.6%-28.8%$90.10M$210,000.00-7.315ADAGAdagene2.0012 of 5 stars$2.02-1.9%$5.00+147.5%+13.9%$89.43M$815,746.000.00260PWUPPowerUp AcquisitionN/A$11.43flatN/A+5.7%$88.81MN/A0.00N/ACTMXCytomX Therapeutics4.3209 of 5 stars$1.13+1.8%$5.77+410.8%-18.7%$88.43M$101.21M6.53170News CoveragePositive NewsME23andMe2.38 of 5 stars$3.36+0.3%$9.40+179.8%-81.5%$87.76M$219.64M-0.13770ANLAdlai Nortye1.5882 of 5 stars$2.36+3.1%$9.00+281.4%-75.7%$87.08M$5M0.00127KPTIKaryopharm Therapeutics3.8062 of 5 stars$0.67-3.7%$5.00+641.6%-16.2%$85.08M$148.44M-0.61380RVPHReviva Pharmaceuticals3.0122 of 5 stars$2.54-2.7%$15.50+510.2%-63.5%$84.94MN/A-2.355High Trading Volume Related Companies and Tools Related Companies Rani Therapeutics Competitors Assertio Competitors Anixa Biosciences Competitors Adagene Competitors PowerUp Acquisition Competitors CytomX Therapeutics Competitors 23andMe Competitors Adlai Nortye Competitors Karyopharm Therapeutics Competitors Reviva Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INKT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
